MedPath

Evaluation of therapeutic effects of adding memantine to stimulants in children with attention deficit hyperactivity disorder

Phase 3
Recruiting
Conditions
Attention-deficit hyperactivity disorder (ADHD).
Attention-deficit hyperactivity disorder, unspecified type
F90.9
Registration Number
IRCT20200825048515N58
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria

Children with attention deficit hyperactivity disorder (ADHD)
Age range 6 to 12 years
Treated with methylphenidate
Parents' consent to participate in the study

Exclusion Criteria

Having major medical disorders (diabetes, asthma, heart disease, seizures)
Having a concomitant psychiatric disorder (mood and anxiety disorders and behavioral and confrontational disorders - disobedience)
Taking another drug in addition to a long-acting stimulant
Mental retardation
Drug sensitivity

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath